Integrins as targets in therapy

Expert Opinion on Therapeutic Patents

Volumn 16, Issue 7, 2006, Pages 963-975

  Bosserhoff, Anja Katrin ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Cardiovascular diseases; Cell attachment; Cell migration; Inflammatory disease; Integrin

Indexed keywords

EID: 49049095586     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.16.7.963     Document Type: Review

References (66)

1. PFARRER C, HIRSCH P, GUILLOMOT M, LEISER R: Interaction of integrin receptors with extracellular matrix is involved in trophoblast giant cell migration in bovine placentomes. Placenta (2003) 24:588-597.
2. SCHMITT DM, BROWER DL: Intron dynamics and the evolution of integrin β-subunit genes: maintenance of an ancestral gene structure in the coral, Acropora millepora. J. Mol. Evol. (2001) 53:703-710.
3. TRIKHA M, TIMAR J, LUNDY SK et al.: The high affinity αIIb β3 integrin is involved in invasion of human melanoma cells. Cancer Res. (1997) 57:2522-2528.
4. KUPHAL S, BAUER R, BOSSERHOFF AK: Integrin signaling in malignant melanoma. Cancer Metastasis Rev. (2005) 24:195-222. • Review article that gives a good introduction into the field of integrins.
5. APLIN JD, HEY NA, GRAHAM RA: Human endometrial MUC1 carries keratan sulfate: characteristic glycoforms in the luminal epithelium at receptivity. Glycobiology (1998) 8:269-276.
6. STUPACK DG, PUENTE XS, BOUTSABOUALOY S, STORGARD CM, CHERESH DA: Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins. J. Cell Biol. (2001) 155:459-470.
7. PANKOV R, CUKIERMAN E, CLARK K et al.: Specific β1 integrin site selectively regulates Akt/protein kinase B signaling via local activation of protein phosphatase 2A. J. Biol. Chem. (2003) 278:18671-18681.
8. KIM S, HARRIS M, VARNER JA: Regulation of integrin αvβ3- mediated endothelial cell migration and angiogenesis by integrin α5β1 and protein kinase A. J. Biol. Chem. (2000) 275:33920-33928.
9. DANEN EH, SONNENBERG A: Integrins in regulation of tissue development and function. J. Pathol. (2003) 201:632-641. • Review article that gives a good introduction into the field of integrins.
10. HODIVALA-DILKE KM, REYNOLDS AR, REYNOLDS LE: Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res. (2003) 314:131-144.
11. BAZAN-SOCHA S, BUKIEJ A, MARCINKIEWICZ C, MUSIAL J: Integrins in pulmonary inflammatory diseases. Curr. Pharm. Des (2005) 11:893-901.
12. DANEN EH: Integrins: regulators of tissue function and cancer progression. Curr. Pharm. Des (2005) 11:881-891.
13. REDDIG PJ, JULIANO RL: Clinging to life: cell to matrix adhesion and cell survival. Cancer Metastasis Rev. (2005) 24:425-439. (Pubitemid 41569982)
14. BRAKEBUSCH C, FASSLER R: β1 integrin function in vivo: adhesion, migration and more. Cancer Metastasis Rev. (2005) 24:403-411.
15. PAULHE F, MANENTI S, YSEBAERT L et al.: Integrin function and signaling as pharmacological targets in cardiovascular diseases and in cancer. Curr. Pharm. Des. (2005) 11:2119-2134. •• Gives an overview on integrins as therapeutic targets.
16. DANEN EH: Integrins: regulators of tissue function and cancer progression. Curr. Pharm. Des. (2005) 11:881-891. • Review article that gives a good introduction into the field of integrins.
17. DANEN EH, TEN BERGE PJ, VAN MUIJEN GN et al.: Emergence of α5β1 fibronectin- and αvβ3 vitronectin-receptor expression in melanocytic tumour progression. Histopathology (1994) 24:249-256. (Pubitemid 24192299)
18. DANEN EH, JANSEN KF, VAN KRAATS AA et al.: Alpha v-integrins in human melanoma: gain of αvβ3 and loss of αvβ5 are related to tumor progression in situ but not to metastatic capacity of cell lines in nude mice. Int. J. Cancer (1995) 61:491-496.
19. SWITALA-JELEN K, DABROWSKA K, OPOLSKI A et al.: The biological functions of β3 integrins. Folia Biol. (Praha). (2004) 50:143-152.
20. CASSERLY IP, TOPOL EJ: Glycoprotein IIb/IIIa antagonists - from bench to practice. Cell Mol. Life Sci. (2002) 59:478-500. •• Gives an overview on integrins as therapeutic targets.
21. HADLEY G: Role of integrin CD103 in promoting destruction of renal allografts by CD8 T cells. Am. J. Transplant. (2004) 4:1026-1032. (Pubitemid 38868591)
22. NOTI JD: Expression and function of the leukocyte integrins in organ transplant rejection. Curr. Med. Chem. (2004) 11:477-490.
23. BAZAN-SOCHA S, BUKIEJ A, MARCINKIEWICZ C, MUSIAL J: Integrins in pulmonary inflammatory diseases. Curr. Pharm. Des. (2005) 11:893-901.
24. STEWART M, THIEL M, HOGG N: Leukocyte integrins. Curr. Opin. Cell Biol. (1995) 7:690-696.
25. CHULUYAN HE, ISSEKUTZ AC: α4-integrin-dependent emigration of monocytes. Springer Semin. Immunopathol. (1995) 16:391-404.
26. SIMON SI, GREEN CE: Molecular mechanics and dynamics of leukocyte recruitment during inflammation. Annu. Rev. Biomed. Eng. (2005) 7:151-185. (Pubitemid 41170187)
27. LEY K: Integration of inflammatory signals by rolling neutrophils. Immunol. Rev. (2002) 186:8-18.:8-18.
28. FLICK MJ, DU X, DEGEN JL: Fibrin(ogen)-αMβ2 interactions regulate leukocyte function and innate immunity in vivo. Exp. Biol. Med. (2004) 229:1105-1110.
29. ROOS D, LAW SK: Hematologically important mutations: leukocyte adhesion deficiency. Blood Cells Mol. Dis. (2001) 27:1000-1004. (Pubitemid 34163968)
30. BUNTING M, HARRIS ES, MCINTYRE TM, PRESCOTT SM, ZIMMERMAN GA: Leukocyte adhesion deficiency syndromes: adhesion and tethering defects involving β2 integrins and selectin ligands. Curr. Opin. Hematol. (2002) 9:30-35.
31. YIP J, SHEN Y, BERNDT MC, ANDREWS RK: Primary platelet adhesion receptors. IUBMB. Life. (2005) 57:103-108.
32. FURMAN MI, FRELINGER AL III, MICHELSON AD: GPIIb/IIIa inhibitor-induced dethrombosis. J. Thromb. Thrombolysis. (2004) 18:11-17.
33. ROSSI ML, ZAVALLONI D: Inhibitors of platelets glycoprotein IIb/IIIa (GP IIb/IIIa) receptor: rationale for their use in clinical cardiology. Mini. Rev. Med. Chem. (2004) 4:703-709.
34. GUTHEIL JC, CAMPBELL TN, PIERCE PR et al.: Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin αvβ3. Clin. Cancer Res. (2000) 6:3056-3061.
35. PATEL SR, JENKINS J, PAPADOPOLOUS N et al.: Pilot study of vitaxin-an angiogenesis inhibitor in patients with advanced leiomyosarcomas. Cancer (2001) 92:1347-1348. (Pubitemid 32861686)
36. POSEY JA, KHAZAELI MB, DELGROSSO A et al.: A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti αvβ3) antibody in patients with metastatic cancer. Cancer Biother. Radiopharm. (2001) 16:125-132.
37. MIKECZ K: Vitaxin applied molecular evolution. Curr. Opin. Investig. Drugs (2000) 1:199-203.
38. TRIKHA M, ZHOU Z, NEMETH JA et al.: CNTO 95, a fully human monoclonal antibody that inhibits αv integrins, has antitumor and antiangiogenic activity in vivo. Int. J. Cancer (2004) 110:326-335.
39. JIN H, VARNER J: Integrins: roles in cancer development and as treatment targets. Br. J. Cancer (2004) 90:561-565. •• Gives an overview on integrins as therapeutic targets.
40. GURRATH M, MULLER G, KESSLER H, AUMAILLEY M, TIMPL R: Conformation/activity studies of rationally designed potent anti-adhesive RGD peptides. Eur. J. Biochem. (1992) 210:911-921.
41. DECHANTSREITER MA, PLANKER E, MATHA B et al.: N-Methylated cyclic RGD peptides as highly active and selective αVβ3 integrin antagonists. J. Med. Chem. (1999) 42:3033-3040.
42. BROOKS PC: Role of integrins in angiogenesis. Eur. J. Cancer (1996) 32A:2423-2429.
43. BAYLESS KJ, SALAZAR R, DAVIS GE: RGD-dependent vacuolation and lumen formation observed during endothelial cell morphogenesis in three-dimensional fibrin matrices involves the αvβ3 and α5β1 integrins. Am. J. Pathol. (2000) 156:1673-1683.
44. CARRON CP, MEYER DM, PEGG JA et al.: A peptidomimetic antagonist of the integrin αvβ3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy. Cancer Res. (1998) 58:1930-1935.
45. REINMUTH N, LIU W, AHMAD SA et al.: Avβ3 integrin antagonist S247 decreases colon cancer metastasis and angiogenesis and improves survival in mice. Cancer Res. (2003) 63:2079-2087.
46. STOELTZING O, LIU W, REINMUTH N et al.: Inhibition of integrin α5β1 function with a small peptide (ATN-161) plus continuous 5-FU infusion reduces colorectal liver metastases and improves survival in mice. Int. J. Cancer (2003) 104:496-503.
47. MCLANE MA, MARCINKIEWICZ C, VIJAY-KUMAR S, WIERZBICKA-PATYNOWSKI I, NIEWIAROWSKI S: Viper venom disintegrins and related molecules. Proc. Soc. Exp. Biol. Med. (1998) 219:109-119. (Pubitemid 28476262)
48. CHANG HH, CHANG CP, CHANG JC, DUNG SZ, LO SJ: Application of recombinant rhodostomin in studying cell adhesion. J. Biomed. Sci. (1997) 4:235-243.
49. MCLANE MA, KUCHAR MA, BRANDO C et al.: New insights on disintegrin-receptor interactions: eristostatin and melanoma cells. Haemostasis (2001) 31:177-182.
50. DANEN EH, MARCINKIEWICZ C, CORNELISSEN IM et al.: The disintegrin eristostatin interferes with integrin α4β1 function and with experimental metastasis of human melanoma cells. Exp. Cell Res. (1998) 238:188-196.
51. HOLZMANN B, GOSSLAR U, BITTNER M: α 4 integrins and tumor metastasis. Curr. Top. Microbiol. Immunol. (1998) 231:125-141.
52. PYTELA R, PIERSCHBACHER MD, ARGRAVES S, SUZUKI S, RUOSLAHTI E: Arginine-glycine-aspartic acid adhesion receptors. Methods Enzymol. (1987) 144:475-489.
53. PLOW EF, PIERSCHBACHER MD, RUOSLAHTI E, MARGUERIE G, GINSBERG MH: Arginyl-glycyl-aspartic acid sequences and fibrinogen binding to platelets. Blood (1987) 70:110-115.
54. MARCINKIEWICZ C, CALVETE JJ, MARCINKIEWICZ MM et al.: EC3, a novel heterodimeric disintegrin from Echis carinatus venom, inhibits α4 and α5 integrins in an RGD-independent manner. J. Biol. Chem. (1999) 274:12468-12473. (Pubitemid 129518012)
55. KANG IC, KIM DS, JANG Y, CHUNG KH: Suppressive mechanism of salmosin, a novel disintegrin in B16 melanoma cell metastasis. Biochem. Biophys. Res. Commun. (2000) 275:169-173.
56. KANG IC, LEE YD, KIM DS: A novel disintegrin salmosin inhibits tumor angiogenesis. Cancer Res. (1999) 59:3754-3760. (Pubitemid 29381883)
57. CORREA MC Jr, MARIA DA, MOURA-DA-SILVA AM, PIZZOCARO KF, RUIZ IR: Inhibition of melanoma cells tumorigenicity by the snake venom toxin jararhagin. Toxicon (2002) 40:739-748.
58. WIERZBICKA-PATYNOWSKI I, NIEWIAROWSKI S, MARCINKIEWICZ C et al.: Structural requirements of echistatin for the recognition of αvβ3 and α5β1 integrins. J. Biol. Chem. (1999) 274:37809-37814.
59. TRIKHA M, DE CLERCK YA, MARKLAND FS: Contortrostatin, a snake venom disintegrin, inhibits β1 integrin-mediated human metastatic melanoma cell adhesion and blocks experimental metastasis. Cancer Res. (1994) 54:4993-4998. (Pubitemid 24289433)
60. MARCINKIEWICZ C, WEINREB PH, CALVETE JJ et al.: Obtustatin: a potent selective inhibitor of α1β1 integrin in vitro and angiogenesis in vivo. Cancer Res. (2003) 63:2020-2023. (Pubitemid 36538600)
61. SHEU JR, LIN CH, PENG HC, HUANG TF: Triflavin, an Arg-Gly-Asp-containing peptide, inhibits the adhesion of tumor cells to matrix proteins via binding to multiple integrin receptors expressed on human hepatoma cells. Proc. Soc. Exp. Biol. Med. (1996) 213:71-79. (Pubitemid 26331085)
62. KNUDSEN KA, TUSZYNSKI GP, HUANG TF, NIEWIAROWSKI S: Trigramin, an RGD-containing peptide from snake venom, inhibits cell-substratum adhesion of human melanoma cells. Exp. Cell Res. (1988) 179:42-49.
63. SOSZKA T, KNUDSEN KA, BEVIGLIA L et al.: Inhibition of murine melanoma cell-matrix adhesion and experimental metastasis by albolabrin, an RGD-containing peptide isolated from the venom of Trimeresurus albolabris. Exp. Cell Res. (1991) 196:6-12.
64. TROCHON-JOSEPH V, MARTEL-RENOIR D, MIR LM et al.: Evidence of antiangiogenic and antimetastatic activities of the recombinant disintegrin domain of metargidin. Cancer Res. (2004) 64:2062-2069.
65. LI L, WARTCHOW CA, DANTHI SN et al.: A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int. J. Radiat. Oncol. Biol. Phys. (2004) 58:1215-1227.
66. LEDEZMA E, APITZ-CASTRO R, CARDIER J: Apoptotic and anti-adhesion effect of ajoene, a garlic derived compound, on the murine melanoma B16F10 cells: possible role of caspase-3 and the α(4)β(1) integrin. Cancer Lett. (2004) 206:35-41.